title: [Cost-effectiveness analysis of routine immunization for varicella in Japan].
abstract: OBJECTIVE
  Immunization for varicella is not currently included in routine immunizations in Japan. This study was conducted to assess test its cost-effectiveness when it becomes a routine.
  
  
  METHODS
  We surveyed and collected information for the year beginning 15th June 2004 in one area. Almost all 11 pediatric clinics or hospitals in the area cooperated in this survey. There was a questionnaire form for families and for doctors. Absent days from routine tasks, i.e., job, housekeeping or study, for family nursing and others were asked on family form. Medical costs and other costs were asked on doctor form. Neither form included the patient's name or name of the medical institution. Doctors explained this survey to patients' family on their first visiting day and asked to cooperate. If they refused the doctor form was also discarded. Since family form was written after recovery and mailed, cooperation in this survey was voluntary. Opportunity cost for family nursing is estimated as opportunity cost based on the 2002 Basic Surveillance of Wage Structure. The burden of sequel cases was estimated assuming six million yen per Quality-adjusted Life Years (QALY). Total number of patients was estimated to be 0.84 million, which includes unvaccinated people in a birth cohort. We adopted incremental benefit cost ratios form societal viewpoint as a measure.
  
  
  RESULTS
  We collected 402 data from the doctor form and 265 from the family form. Total disease burden in all of Japan is estimated to be 52.2 billion yen, but opportunity cost accounted for 80%. The incremental benefit cost rations averaged more than 4 when vaccination cost is assumed to be five to twelve thousand yen. The lower limit of the confidence intervals is about 1.5.
  
  
  CONCLUSIONS
  The disease burden of varicella was greater than measles in 2000, when there were measles 0.2 million patients. The incremental benefit cost ratio showed that there will almost surely be an additional benefit due to routine immunization is greater than the additional cost. Therefore, we found strong evidence for routine immunization for varicella.
authors.affiliation: National Institute of Infectious Diseases.
authors.forename: Tamie
authors.initials: T
authors.lastname: Sugawara
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Ohkusa
authors.forename: Kaoru
authors.initials: K
authors.lastname: Oikawa
authors.forename: Noriyuki
authors.initials: N
authors.lastname: Haneda
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Kikuchi
authors.forename: Fumihide
authors.initials: F
authors.lastname: Kato
authors.forename: Seiji
authors.initials: S
authors.lastname: Yamaguchi
authors.forename: Nobuhiko
authors.initials: N
authors.lastname: Okabe
mesh_terms: D002644:Chickenpox / Q000191:economics; D019433:Chickenpox Vaccine / Q000008:administration & dosage*; D003362:Cost-Benefit Analysis; D003625:Data Collection; D005260:Female; D006801:Humans; D007115:Immunization Schedule; D007564:Japan; D008297:Male
chemical_list: D019433:Chickenpox Vaccine